Robert R. Ford, M.D. received his B.S. degree from Rutgers University in 1979 and his M.D. degree from Robert Wood Johnson Medical School in 1983. He completed an internship in Internal Medicine at Robert Wood Johnson University Medical Center and University Medical Center at Princeton. From 1984 to 1988 he completed a residency in Diagnostic Radiology at Cornell University Medical Center-New York Hospital, Memorial Sloane Kettering Cancer Center, and the Hospital for Special Surgery.

He joined Princeton Radiology Associates (PRA) in 1988.  In 1998, Dr. Ford founded RadPharm, an Imaging Core Lab dedicated to the Independent Review of Diagnostic Imaging studies for the Pharmaceutical and Regulatory Agencies, primarily the United States Food and Drug Administration (USFDA).  Between 1998 and 2008, while still a member of PRA, Dr Ford functioned as President and Chief Medical Officer (CMO) of RadPharm.  In the capacity as CMO, Dr. Ford was a reviewer or supervised the independent radiologic review of images from no fewer than 295 clinical trials involving tens of thousands of patients primarily in the oncology therapeutic area.  In addition during that time he worked with the USFDA and Pharmaceutical Companies for the approval of Herceptin, Eloxatin, Velcade, Sutent, Vectibix, Ixempra, Treanda, Doxil, Avastin and Pegloticase.

Dr. Ford was an author of the Response Evaluation Criteria of Solid Tumors (RECIST 1.1) an internationally accepted Response Criteria that is used to standardize patient response to therapy. 

Dr. Ford returned to full time clinical practice with Princeton Radiology Associates in 2008.  Dr. Ford is a Clinical Instructor in the Department of Diagnostic Radiology at the Robert Wood Johnson University Hospital. He is a radiologist on staff at Carrier Clinic and Princeton University, and is an Attending Radiologist at University Medical Center at Princeton. Dr. Ford is certified by the National Board of Medical Examiners. He is board certified in Diagnostic Radiology and has a certificate of added qualifications in Neuroradiology from the American Board of Radiology.

PUBLICATIONS:

Discordance between BICR Readers: Understanding the causes and implementing processes to mitigate preventable sources of discordance
Kristin Borradaile, Robert Ford, MD, Michael O’Neal, MD, Kevin Byrne, MD

Applied Clinical Trials – November 2010

New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (version 1.1)
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shanker, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij

European Journal of Cancer 45 (2009) 228-247

Lessons Learned from Independent Central Review
R. Ford, L. Schwartz, J. Dancey, L.E. Dodd, E.A. Eisenahuer, S. Gwyther, L. Rubinstein, D. Sargent, L. Shanker, P. Therasse, J. Verweij

European Journal of Cancer 45 (2009) 268-274

Individual Patient Data Analysis to Assess Modifications to the RECIST Criteria
Jan Bogaerts, Robert Ford, Dan Sargent, Lawrence H. Schwartz, Larry Rubinstein, Denis Lacombe, Elizabeth Eisenhauer, Jaap Verweij, Patrick Therasse, for the RECIST Working Party

European Journal of Cancer 45 (2009) 248-260

Evaluation of Lymph Nodes with RECIST 1.1
L.H. Schwartz, J. Bogaerts, R. Ford, L. Shankar, P. Therasse, S. Gwyther, E.A. Eisenhauer

European Journal of Cancer 45 (2009) 261-267

Recommendations for the Assessment of Progression in Randomised Cancer Treatment Trials
J.E. Dancey, L.E. Dodd, R. Ford, R. Kaplan, M. Mooney, L. Rubinstein, L.H. Schwartz, L. Shankar, P. Therasse

European Journal of Cancer 45 (2009) 281-289

Report of Task Force II: Best Practices in the Use of Medical Imaging Techniques in Clinical Trials: Consensus from a Public Meeting, October 16-17, 2007, The Medical Imaging Stakeholders Call for Action: Harmonization Across Key Elements and Integration of Imaging in Therapeutic Development – Pharmaceutical Industry, CRO, FDA, and Allied Working Groups Collaborate for Regulatory Guidance
Robert Ford, MD, David Mozley, MD

Drug Information Journal, Vol. 42, pp. 515-523, 2008


POSTER PRESENTATIONS:

Analysis of the Cause of Discordance between Two Radiologists on the Assessment of Radiographic Response and Progression for Subjects Enrolled in Breast Cancer Clinical Trials Employing Blinded Independent Central Review
Kristin Borradaile, MS, Robert Ford, MD, Michael O’Neal, MD, Kevin Byrne, MD

2010 – American Society of Clinical Oncology Annual Meeting, General Poster Session

Analysis of the Rate of Non-target Disease Progression in Patients with Stable or Responding Target Disease by the Response Evaluation Criteria in Solid Tumors (RECIST)
Kristin Borradaile, MS, Robert Ford, MD

2009 – American Society of Clinical Oncology Annual Meeting, General Poster Session

The Impact of the Inclusion of Clinical Data Review on Overall Radiographic Response and Progression in Oncology Clinical Trials as Assessed by Blinded Independent Central Review
Nicolette Wangler, BS, Kristin Borradaile, MS, Robert Ford, MD

2009 – American Society of Clinical Oncology Annual Meeting, Poster Discussion

First Application of Computed-Assisted Analysis of Digital Photographs for Assessing Tophus Response: Phase 3 Studies of Pegloticase in Treatment Failure of Gout
A.N. Maroli, R. Waltrip, M. Alton, Herbert S. B. Baraf, B. Huang, C. Rehrig, R. Ford

2009 – ACR/ARHP Annual Scientific Meeting

Analysis of the Rate of Missing Data, the Rate of Discordance between Readers, and the Rate of Site versus Central Discordance in Clinical Studies of Recently Approved Breast Cancer Agents that have Used Blinded Independent Central Review
Kristin Borradaile, Kathy-Ann Cadogan, MBBS, Stacie Somers, Robert Ford, MD

2008 – San Antonio Breast Cancer Symposium, General Poster Session

Inter-observer Variability in Radiographic Assessment of Response in Chemotherapy Trials for Pancreatic Cancer
Brian Baumann, AB, Robert Ford, MD, Kathy Dasse, PharmD, Kathy Zhou, PhD, Ruth Feldman, MD

2007 – American Society of Clinical Oncology Annual Meeting, General Poster Session

Evaluation of the Number of Target Lesions to Analyze in Time to Progression by RECIST
Mithat Gonen, PhD, Lawrence Schwartz, MD, Robert Ford, MD

2007 – American Society of Clinical Oncology Annual Meeting, General Poster Session

A Retrospective Exploratory Study of the Variability of Radiologists Measurements in a Selected Subgroup of Subjects Enrolled in a Clinical Trial
Robert W. Ford, Kathy Zhou, PhD, Robert R. Ford, MD

2007 – American Society of Clinical Oncology Annual Meeting, General Poster Session